- Home
- AIRT vs IVVD Comparison
AIRT vs IVVD Comparison
Compare AIRT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- IVVD
- Stock Information
- Founded
- AIRT 1980
- IVVD 2020
- Country
- AIRT United States
- IVVD United States
- Employees
- AIRT N/A
- IVVD N/A
- Industry
- AIRT Air Freight/Delivery Services
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- IVVD Health Care
- Exchange
- AIRT Nasdaq
- IVVD Nasdaq
- Market Cap
- AIRT 59.6M
- IVVD 63.4M
- IPO Year
- AIRT N/A
- IVVD 2021
- Fundamental
- Price
- AIRT $25.42
- IVVD $1.16
- Analyst Decision
- AIRT
- IVVD Strong Buy
- Analyst Count
- AIRT 0
- IVVD 4
- Target Price
- AIRT N/A
- IVVD $3.64
- AVG Volume (30 Days)
- AIRT 1.5K
- IVVD 13.8M
- Earning Date
- AIRT 08-13-2025
- IVVD 08-14-2025
- Dividend Yield
- AIRT N/A
- IVVD N/A
- EPS Growth
- AIRT N/A
- IVVD N/A
- EPS
- AIRT N/A
- IVVD N/A
- Revenue
- AIRT $296,309,000.00
- IVVD $46,210,000.00
- Revenue This Year
- AIRT N/A
- IVVD $385.94
- Revenue Next Year
- AIRT N/A
- IVVD $62.62
- P/E Ratio
- AIRT N/A
- IVVD N/A
- Revenue Growth
- AIRT 5.14
- IVVD 1941.08
- 52 Week Low
- AIRT $14.56
- IVVD $0.35
- 52 Week High
- AIRT $26.70
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- AIRT 64.96
- IVVD 66.84
- Support Level
- AIRT $22.63
- IVVD $0.96
- Resistance Level
- AIRT $25.50
- IVVD $1.14
- Average True Range (ATR)
- AIRT 0.46
- IVVD 0.14
- MACD
- AIRT 0.21
- IVVD 0.05
- Stochastic Oscillator
- AIRT 98.20
- IVVD 93.12
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.